NCT02810743 - Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | Biotech Hunter

Enrollment

174

Participants

Timeline

Start Date

January 25, 2017

Primary Completion Date

July 1, 2025

Study Completion Date

December 1, 2033

Conditions

Breast Cancer

Interventions

DRUG

ddAC-CP-Olaparib

DRUG

ddAC-mini CTC

ddAC - mini CTC

Trial Locations (11)

Institut Paoli Calmettes, Marseille

Hopital Tenon, University Marie-Curie, Paris

University Medical Center Groningen, Groningen

Maastricht University Medical Center, Maastricht

Medical spectrum Twente, Enschede

Antoni van Leeuwenhoek, Amsterdam

AZVU, Amsterdam

LUMC, Leiden

Radboud UMC, Nijmegen

Erasmus Medical Center Cancer Institute, Rotterdam

University Medical Center Utrecht, Utrecht

All Listed Sponsors

lead

The Netherlands Cancer Institute

OTHER